Asthma, is a very prevalent chronic pulmonary disease, affecting over 230 million people worldwide, with available treatments limited to symptoms relief (1). Considering this serious world situation, Wang et al . highlighted the nanotechnology related to delivery of drugs or biological materials, reducing side toxic effects, increasing drug bioavailability, thus improving asthma treatment. However, in this editorial comment, we sumarize the challenges that need to be overcome to nanotherapy become pertinent in clinical practice.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: